Back to search results

Study of RAS(ON) Inhibitors in Gastrointestinal Cancers

This study is testing new treatments for gastrointestinal cancers, including colorectal cancer and pancreatic cancer, that have a specific change called a RAS mutation. Researchers are looking at the safety, how well the body handles the drugs (tolerability and pharmacokinetics), and if they shrink tumors. The main drug being studied is RMC-6236, which is an oral tablet. It's being combined with standard treatments like mFOLFOX6, bevacizumab, mFOLFIRINOX, or cetuximab, or with other new agents. The study will track side effects (adverse events) for up to 3 years and serious side effects (dose-limiting toxicities) for 28 days. You may be able to join if you are 18 or older, have a good performance status (ECOG PS 0-1), and have a confirmed RAS-mutated pancreatic or colorectal cancer. The current status of the study is unclear, and it plans to enroll 1130 participants.

Study design
This is an open-label platform study, meaning both you and your doctors will know which treatments you are receiving. It is designed to test different combinations of RAS(ON) inhibitors with other cancer drugs.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Adverse events will be measured for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06445062

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Revolution Medicines, Inc.
~1,130 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:RMC-6236mFOLFOX6 regimenbevacizumabmFOLFIRINOX regimencetuximabgemcitabine

At a glance

Recruiting sites
32 of 32 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events
Measured over Up to 3 years
+1 more outcome measured

Conditions

Colorectal Cancer
CRC
Pancreatic Ductal Adenocarcinoma
PDAC
Gastrointestinal Cancer
Metastatic Pancreatic Ductal Adenocarcinoma

Explore related trials

Colorectal CarcinomaPancreatic Ductal AdenocarcinomaSolid Neoplasm

NCT06445062

Where you'd take part

This study runs at 32 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Atlantic Health System

    Morristown, New Jerseystudy coordinator listed

    Recruiting

  • Baylor College of Medicine

    Houston, Texasstudy coordinator listed

    Recruiting

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center

    Los Angeles, Californiastudy coordinator listed

    Recruiting

  • Columbia University Medical Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • Duke University Medical Center

    Durham, North Carolinastudy coordinator listed

    Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washingtonstudy coordinator listed

    Recruiting

  • HonorHealth Research Institute

    Scottsdale, Arizonastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Study Director · STUDY_DIRECTOR · Revolution Medicines

Who to contact

Revolution Medicines
[email protected]
1-844-2-REVMED
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

≥ 18 years of age
ECOG PS is 0 to 1
Adequate organ function as outlined by the study
Pathologically or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A, B, and C)
Presence of RAS G12D mutation (Subprotocol D, E, F)

Exclusion

Primary central nervous system (CNS) tumors
Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
Major surgery within 28 days of first dose

What this trial measures

  • Adverse eventsUp to 3 years

    Evaluate the safety and tolerability in the study population characterized by incidence, abnormal laboratory assessments, severity, and seriousness of adverse events in relation to the study treatment.

  • Dose limiting toxicities28 days

    Number of participants with dose limiting toxicities